Path Corporation
Joint Research Agreement with Subsidiary and Tokyo Medical University | July 21, 2026
RMDC has concluded a joint research agreement with Tokyo Medical University to develop stem cell culture technology for regenerative medicine, aiming to create new culture devices. The research period is from July 2026 to June 2027, collaborating with the world-renowned Professor Ochiya to enhance technological capabilities in the regenerative medicine business.
Key Figures
- Research Period: July 1, 2026 to June 30, 2027
- Joint Research Partners: Tokyo Medical University Institute of Medical Science and RMDC Hyogo CPF
- Research Contract Signing Date: July 21, 2026
AI要約
Overview of Business Activities
RMDC has entered into a research contract with Tokyo Medical University to develop stem cell culture technology for use in regenerative medicine. The research period runs from July 1, 2026, to June 30, 2027, leveraging insights from the globally renowned Professor Ochiya to optimize extracellular vesicles and culture devices. This aims to improve technological capabilities in the regenerative medicine field and strengthen our business foundation.
Future Outlook and Impact on the Company
While this research is expected to contribute to medium- to long-term corporate value and business expansion, its impact on the consolidated results for the fiscal year ending March 2027 is anticipated to be minimal. Going forward, sharing research成果 and rights is expected to strengthen competitiveness in regenerative medicine related businesses and provide a foundation for new business development.
PATH
Company overview · Stock price · Financial data · All IR
